Please assess the completion status of the following clinical trial:

Trial Title: Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven GBM with central pathology review at Dartmouth-Hitchcock Medical Center (DHMC)~* Tumor specimen obtained at the time of surgery adequate for vaccination~* 18 years of age or older~* Karnofsky Performance Status 60% or greater~* Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10 9th/L~* Platelets greater than or equal to 100 x 10 9th/L~* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) less than or equal to 5 times the upper limits of normal (ULN)~* Total bilirubin less than or equal to 1.5 times ULN~* Serum creatinine less than or equal to 1.5 times ULN, OR estimated creatinine clearance greater than or equal to 60 mL/min~* No known immunosuppression other than chemo-related~* Negative HIV serologies~* No evidence of acute or chronic hepatitis on standard hepatitis C and B screening tests~* No chemotherapy within four weeks prior to leukapheresis~* Radiotherapy at outside institution is permitted if tissue was obtained at time of surgery at DHMC and patient is willing to follow-up per protocol~* Off steroids for at least two weeks before leukapheresis~* No second malignancies except non-melanoma skin cancer, and non-invasive cancer such at cervical CIS, superficial bladder cancer or breast CIS~* Negative serum or urine pregnancy test for women of childbearing potential~* No serious uncontrolled medical disorder or active infection~* All patients must give informed consent~* No history of clinical evidence of active autoimmune disease~Exclusion Criteria:~* Invasive cancers in the past 5 years~* Rheumatologic/autoimmune disease~* Pregnancy or unwillingness to remain on acceptable form of birth control during study~* Major cardiac, pulmonary, or other systemic disease; viral hepatitis; HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).